Be Counted! Campaign Brings Together the Psoriatic Arthritis Community to Increase Understanding of This Chronic, Autoimmune ...
January 22 2016 - 08:00AM
Business Wire
Initiative Urges Public to Harness Their
Online Power to Support the Community in Their Efforts to Generate
Awareness
Celgene Corporation (NASDAQ:CELG) today announced the launch of
Be Counted!, an educational initiative that unites advocates,
experts, and patients to raise awareness of psoriatic arthritis
(PsA) and rallies public support of this chronic, autoimmune
disease. Together, the community has created a social initiative at
PsACounts.com that highlights different perspectives on the disease
and urges people to get involved and help spread the word of the
program via their social media channels.
PsA is a painful and debilitating chronic condition that affects
up to 1 million Americans, but this number may be higher given the
disease is often misdiagnosed and underreported. In fact, the
prevalence of PsA is higher than the number of people living with
more well-known, serious conditions such as multiple sclerosis,
Lyme disease, and amyotrophic lateral sclerosis (ALS) combined. PsA
may impact patients’ mobility in their daily lives; at the most
basic level, some are unable to walk easily or climb stairs.
“People living with PsA often share that, in addition to their
physical symptoms, they feel isolated and alone. This is often
because PsA impacts people who don’t yet have peers facing serious
or long-lasting health conditions – so they do not know who to turn
to for support.” said Jason Faller, M.D., Mount Sinai Roosevelt
Medical Center. “Also, many disclose that their PsA is confused
with osteoarthritis – also known as “age-related” or "wear and
tear" arthritis – and other autoimmune conditions. However, PsA is
a disease that is different from other arthritic or psoriatic
conditions and can present significant challenges to those living
with the disease.”
The Be Counted! campaign aims to reinforce that PsA is a disease
people should understand because of its significant prevalence and
the distinct way it impacts the body and those living with it.
Insights from PsA patients, advocates, and rheumatologists show the
profound impact of living with a misunderstood disease and the
importance of community, treatment, and disease management. People
are encouraged to show their support by viewing the videos at
PsACounts.com and sharing on their social channels, leveraging the
power of their online network to increase awareness of PsA. The
site also features a map demonstrating how awareness is increasing
across the country by counting video views.
“There is no cure for psoriatic arthritis, and that’s why it’s
so important for those connected to the disease – including
advocacy groups, healthcare providers, and patients – and the
general public to work together to create an environment that
supports the PsA community and helps them to manage their disease,”
said Randy Beranek, President and CEO, National Psoriasis
Foundation.
“There are treatments to help manage symptoms of PsA. People
with PsA should speak with their doctor about their condition,”
said Renae R., a psoriatic arthritis patient. “However, I continue
to struggle with others’ misperceptions of the disease. I am so
excited that Celgene has introduced the Be Counted! campaign
because it will help educate people about PsA and help them
understand that it is a disease that counts.”
“Celgene believes that addressing the needs of people living
with PsA requires patients to have not only access to different
treatment options, but also a better understanding of the disease
and its impact,” said Terrie Curran, Corporate Vice President,
Inflammation & Immunology, Celgene. “The Be Counted! campaign
was designed to support PsA patients and the larger community by
providing much-needed education and perspective on the
disease.”
To learn more about the campaign and to spread the word about
PsA, visit PsACounts.com.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in
the discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases
through next-generation solutions in protein homeostasis,
immuno-oncology, epigenetics, immunology and neuro-inflammation.
For more information, please visit www.celgene.com. Follow Celgene
on Social Media: @Celgene, Pinterest, LinkedIn, FaceBook and
YouTube.
Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
“expects,” “anticipates,” “believes,” “intends,” “estimates,”
“plans,” “will,” “outlook” and similar expressions. Forward-looking
statements are based on management’s current plans, estimates,
assumptions, and projections, and speak only as of the date they
are made. We undertake no obligation to update any forward-looking
statement in light of new information or future events, except as
otherwise required by law. Forward-looking statements involve
inherent risks and uncertainties, most of which are difficult to
predict and are generally beyond our control. Actual results or
outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual
Report on Form 10-K and other reports filed with the Securities and
Exchange Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160122005458/en/
Celgene CorporationInvestors:Patrick E. Flanigan IIIVice
President, Investor Relations908-673-9969orMedia:Catherine
CantoneDirector, Corporate Communications732-564-3592
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Feb 2024 to Mar 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2023 to Mar 2024